VitaStemNCT06508099
Vitamin A and D Supplementation in Allogeneic HCT
StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 5 more changesShow less
- Enrollment closed, study ongoing
- Primary completion date changed from estimate of May 2026 to Nov 17, 2026
- Study completion pushed from May 2027 to Nov 17, 2027
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised
- Notable Eligibility criteria shortened, about 1 word
- Secondary endpoints: details revised at 1 of 9 entries
- Study description revised
- Study title expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Cumulative incidence of gastrointestinal acute GVHD
Timeframe: 125 days
Secondary (9)
Incidence of HSCT-associated adverse events
Infectious complications
Overall survival
Event-free survival
Overall cumulative incidence of acute GVHD grade II-IV
Show 4 moreShow less
Incidence of moderate and severe chronic GVHD
Non-relapse mortality analysis
GVHD-relapse-free survival analysis
Cumulative incidence of primary and secondary graft failure
Arms and interventions
Vitamin supplementationExperimental
vitamin A 300 000 IU and vitamin D 100 000 IU on days -14 to -8 before transplantation
Routine careNo intervention
Routine care
Drugs: Vitamin A, Vitamin D3
Sites
1 site in 1 country
- RM Gorbacheva Research InstituteSaint Petersburg, Russia